A GalNAc-conjugated RNA editing oligonucleotide achieves >90% editing of pathogenic SERPINA1 transcripts, restoring Alpha-1 Antitrypsin function in AATD models
May 15, 2026 from 4:30 PM to 4:45 PM EDT
Expanding Cell and Gene Therapy Through Therapeutic RNA and Epigenome Engineering